BeiGene | A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

⟵ Back to Search Results

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Beigene Study ID

BGB-11417-105

ClinicalTrials.gov ID

NCT04973605

EudraCT Number

2023-507751-30-00

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents